MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Nephros Cost of Revenue 2011-2026 | NEPH
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Nephros
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.83 M | 5.24 M | 4.58 M | 3.65 M | 4.25 M | 2.48 M | 1.52 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.83 M | 1.52 M | 3.94 M |
Quarterly Cost of Revenue Nephros
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.85 M | 1.62 M | 1.72 M | - | 1.37 M | 1.34 M | 1.34 M | - | 1.55 M | 1.47 M | 1.59 M | - | 1.65 M | 1.46 M | 1.11 M | - | 1.22 M | 991 K | 1.15 M | - | 896 K | 682 K | 1.04 M | - | 1.28 M | 942 K | 771 K | - | 772 K | 536 K | 518 K | - | 384 K | 342 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.85 M | 342 K | 1.14 M |
Cost of Revenue of other stocks in the Medical instruments industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
107 K | - | - | $ 810 M |  USA |
 |
iRhythm Technologies
IRTC
|
220 M | $ 125.96 | 2.95 % | $ 4.03 B | USA |
 |
Alcon
ALC
|
3.58 B | $ 76.01 | 0.28 % | $ 40.4 B |  Schweiz |
 |
Ekso Bionics Holdings
EKSO
|
5.95 M | $ 11.37 | 3.46 % | $ 27.6 M | USA |
 |
Repro Med Systems
KRMD
|
15.5 M | $ 4.06 | 2.53 % | $ 188 M | USA |
 |
The Cooper Companies
COO
|
1.41 B | $ 64.34 | -0.12 % | $ 12.8 B | USA |
 |
Microbot Medical
MBOT
|
1.91 M | $ 2.17 | -1.36 % | $ 99.4 M |  Israel |
 |
Milestone Scientific
MLSS
|
2.57 M | $ 0.34 | 6.28 % | $ 27.9 M | USA |
 |
Haemonetics Corporation
HAE
|
612 M | $ 60.48 | 0.92 % | $ 3.04 B | USA |
 |
electroCore
ECOR
|
4.24 M | $ 6.07 | -1.7 % | $ 51.5 K | USA |
 |
ICU Medical
ICUI
|
1.41 B | $ 122.85 | -1.58 % | $ 3.03 B | USA |
 |
Envista Holdings Corporation
NVST
|
1.23 B | $ 26.77 | -0.11 % | $ 4.5 B | USA |
 |
Isoray
ISR
|
3.13 M | - | 0.03 % | $ 108 M | USA |
 |
Intuitive Surgical
ISRG
|
3.42 B | $ 470.99 | -2.33 % | $ 168 B | USA |
 |
Glaukos Corporation
GKOS
|
75.6 M | $ 122.07 | 0.34 % | $ 5.91 B | USA |
 |
STERIS plc
STE
|
3.06 B | $ 222.19 | 0.2 % | $ 21.9 B | USA |
 |
Teleflex Incorporated
TFX
|
872 M | $ 135.07 | -1.09 % | $ 6.03 B | USA |
 |
Masimo Corporation
MASI
|
1.09 B | $ 178.66 | 0.02 % | $ 9.52 B | USA |
 |
InfuSystem Holdings
INFU
|
47.3 M | $ 10.66 | 3.09 % | $ 220 M | USA |
 |
Merit Medical Systems
MMSI
|
778 M | $ 67.43 | -1.68 % | $ 3.99 B | USA |
 |
Utah Medical Products
UTMD
|
16.5 M | $ 66.78 | -0.58 % | $ 216 M | USA |
 |
Pulse Biosciences
PLSE
|
539 K | $ 22.65 | -1.61 % | $ 1.53 B | USA |
 |
West Pharmaceutical Services
WST
|
1.97 B | $ 302.2 | -1.29 % | $ 21.8 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
1.84 B | $ 11.96 | 0.42 % | $ 2.38 B | USA |
 |
Retractable Technologies
RVP
|
38.2 M | $ 0.64 | -0.92 % | $ 19.2 M | USA |
 |
Pro-Dex
PDEX
|
47.1 M | $ 51.96 | -0.27 % | $ 171 M | USA |
 |
LeMaitre Vascular
LMAT
|
71.1 M | $ 114.52 | 0.94 % | $ 2.59 B | USA |
 |
Predictive Oncology
POAI
|
72.6 K | - | - | $ 31.1 M | USA |
 |
STAAR Surgical Company
STAA
|
57 M | $ 26.68 | 3.93 % | $ 1.32 B | USA |
 |
BioLife Solutions
BLFS
|
8.76 M | $ 21.41 | 0.14 % | $ 986 M | USA |
 |
Stereotaxis
STXS
|
15.3 M | $ 1.93 | - | $ 176 M | USA |
 |
Baxter International
BAX
|
7.86 B | $ 18.49 | 1.82 % | $ 9.49 B | USA |
 |
ResMed
RMD
|
1.55 B | $ 222.02 | 1.05 % | $ 32.4 B | USA |
 |
AtriCure
ATRC
|
134 M | $ 29.04 | -0.82 % | $ 1.39 B | USA |
 |
Harvard Bioscience
HBIO
|
36.6 M | $ 6.83 | -0.44 % | $ 303 M | USA |
 |
NeuroMetrix
NURO
|
1.35 M | - | 5.05 % | $ 9.02 M | USA |
 |
AngioDynamics
ANGO
|
135 M | $ 11.09 | -0.09 % | $ 453 M | USA |
 |
Becton, Dickinson and Company
BDX
|
11.9 B | $ 150.22 | -1.25 % | $ 43.2 B | USA |
 |
OraSure Technologies
OSUR
|
66.8 M | $ 3.01 | 0.33 % | $ 221 M | USA |
 |
Repligen Corporation
RGEN
|
354 M | $ 118.29 | 0.59 % | $ 6.59 M | USA |